Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.

Ann Clin Transl Neurol · 2025 · PMC12040499 · PMID 39949066

Europe PMC DOI

hedged sentences

0.0660

closest p · 1.3× alpha

0.1630

boldest claim

The sentences

showed a trendp = 0.066so close (0.05 < p ≤ 0.1)

In refractory IIH cases, while the liraglutide group showed a trend toward improvement at 3 months (RR 0.791, 95% CI 0.615–1.017, p = 0.066) and 24 months (RR 0.913, 95% CI 0.778–1.072, p = 0.267), these reductions also did not achieve statistical significance.

also in 53,322 other papers

a nonsignificant trendp = 0.163not close (p > 0.1)

For visual disturbances and blindness, we observed a nonsignificant trend toward risk reduction at 3 months (RR 0.588, 95% CI 0.276–1.254, p = 0.163) and 24 months (RR 0.788, 95% CI 0.490–1.268, p = 0.324).

also in 5,406 other papers

did not reach statistical significanceno p-value reported

While improvements were observed in visual disturbances, headache symptoms, and refractory IIH cases, these did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.